StreetAlpha.app
Home › Stocks › PAVM

PAVmed Inc. (PAVM)

$1.47
▼ −16.29%
LAST CLOSE · NOV 17

PAVmed develops medical devices, diagnostics and digital health tools, including the EsoGuard test for esophageal precancer screening. It last closed at $1.47 on Nov 17, down 16.29% on the day.

AI Auto Pilots
Is PAVM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$148K
+410.3% vs a year ago
Net income
−$18.4M
−693.3% vs a year ago
EPS (diluted)
−$7.37
−108.0% vs a year ago
Free cash flow
−$4.5M
−3024.3% margin
Valuation
Market cap
$11.7M
8.0M shares
P/E
–
No P/E while losing money
Price to sales
79.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$3.6M
At Sep 30
Shareholder equity
$27.5M
Shares outstanding
8.0M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $500K$500KFY2021FY2022: $377K$377KFY2022FY2023: $2.5M$2.5MFY2023FY2024: $3.0M$3.0MFY2024FY2025: $71K$71KFY2025

From PAVM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PAVM in the past 90 days, not enough for a consensus
Average 12-month target
$57.00
▲ 3790.8% upside

Based on 1 analyst who set a price target on PAVM in the past 90 days. The average target is $57.00, with a high of $57.00 and a low of $57.00, compared with the last close of $1.47.

Low $57.00Avg $57.00High $57.00
Blue marker: last close $1.47
Highest target$57.00
Average target$57.00
Lowest target$57.00
Latest rating changes
Ascendiant CapitalTarget raised
Aug 27Buy$56 → $57
Ascendiant CapitalMaintained
Jun 8Buy$56
DateFirmActionRatingPrice target
Aug 27Ascendiant CapitalTarget raisedBuy$56 → $57
Jun 8Ascendiant CapitalMaintainedBuy$56
Loading…

Technical Analysis

PAVM · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 24% below its 20 day and 87% below its 50 day average. It is 320% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 34), near oversold. The nearest support is the Pivot S1 at $1.36, and the nearest resistance the Pivot at $1.55.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 20.4%/day
Key levels
$28.4452 week high+1834.7%
$6.15200 day average+318.4%
$4.33Swing high (Sep 22)+194.6%
$3.98100 day average+170.7%
$2.7350 day average+85.7%
$1.8220 day average+23.8%
$1.66Pivot R1+12.9%
$1.55Pivot+5.4%
$1.47Last close
$1.36Pivot S1−7.5%
$1.1752 week low−20.4%
$1.17Swing low (Nov 11)−20.4%
Indicators
RSI (14)34.08Weak, oversold below 30Neutral
MACD-0.35Above its signal lineBullish
Stochastic40.1Middle of its rangeNeutral
ADX (14)50.9Strong downtrend
Williams %R-73.7Oversold below −80, overbought above −20Neutral
CCI (20)-80.8Oversold below −100, overbought above 100Neutral
Rate of change−21.7%Change over 10 sessionsBearish
ATR (14)$0.30Typical daily range, 20.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PAVM

What happened before

See how PAVM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PAVM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PAVM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PAVM in the last 90 days.

Loading…

See today’s whale options flow across the market →

PAVM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●8 buying vs 7 selling
  • ●Held by funds +0.4 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2421+14.3%
In funds' top 1000–
Held by funds12.1%11.7%+0.4 pts
New / increased4 / 46 / 6−33.3%
Reduced / sold out4 / 33 / 5−12.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PAVM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PAVM is in one of them and how their past PAVM trades turned out.

PAVM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PAVM in an article yet. Here's the latest on the wider market.

About PAVmed

PAVmed is a New York based company that works in medical devices, diagnostics and digital health. Its main product is the EsoGuard test, a DNA test run on cells collected with the EsoCheck device, which is offered to doctors, health systems, employers and patients to screen people with chronic acid reflux for esophageal precancer. Its Veris Health unit provides digital tools for cancer patients during and after treatment. The company is also developing PortIO, an implantable vascular access device.

Headquarters
New York, NY